<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes and clinical manifestations of acromegaly</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes and clinical manifestations of acromegaly</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes and clinical manifestations of acromegaly</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shlomo Melmed, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence Katznelson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acromegaly is the clinical syndrome that results from excessive secretion of growth hormone (GH) [<a href="#rid1">1</a>]. Its annual incidence is six to eight per million people [<a href="#rid2">2</a>]. The mean age at diagnosis is 40 to 45 years.</p><p>The causes and clinical features of acromegaly will be reviewed here. The laboratory diagnosis and treatment of acromegaly are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6635.html" rel="external">"Diagnosis of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CAUSES</span><span class="headingEndMark"> — </span>The most common cause of acromegaly is a somatotroph (growth hormone [GH]-secreting) adenoma of the anterior pituitary. These adenomas account for approximately one-third of all hormone-secreting pituitary adenomas  (<a class="graphic graphic_table graphicRef73104" href="/z/d/graphic/73104.html" rel="external">table 1</a>). GH excess that occurs before fusion of the epiphyseal growth plates in a child or adolescent is called pituitary gigantism. (See  <a class="medical medical_review" href="/z/d/html/5855.html" rel="external">"Pituitary gigantism"</a>.)</p><p>An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas [<a href="#rid3">3-5</a>]. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division in and excessive GH secretion by these adenomas.</p><p>The pituitary tumor transforming gene is also overexpressed in most human somatotroph adenomas [<a href="#rid6">6</a>]. It also appears to play a role in tumor invasiveness since expression is increased in tumors that invade the sphenoid bone.</p><p>Microduplications on chromosome Xq26.3 have been associated with excessive GH in children with gigantism and in adults with acromegaly. In a study of 43 patients with gigantism due to GH excess, microduplications in the Xp26.3 region that includes the <em>GPR101</em> (G protein-coupled receptor 101) gene were identified in 13 patients (termed X-linked acrogigantism [X-LAG]) [<a href="#rid7">7</a>]. All patients identified with this microduplication had disease onset before five years of age, and the G protein-coupled receptor was overexpressed in the patients' pituitary lesions (see  <a class="medical medical_review" href="/z/d/html/5855.html" rel="external">"Pituitary gigantism"</a> and  <a class="medical medical_review" href="/z/d/html/16974.html" rel="external">"Sex chromosome abnormalities", section on 'Xq26.3 microduplication'</a>). In the same study, a recurrent mutation in <em>GPR101</em> was found in 11 of 248 adult patients with acromegaly (mostly in pituitary tumors). Other known causes of acromegaly, all very rare, are excess secretion of GH-releasing hormone (GHRH) by hypothalamic tumors, ectopic GHRH secretion by neuroendocrine tumors such as carcinoid tumors or small-cell lung cancers, and ectopic secretion of GH by neuroendocrine tumors [<a href="#rid8">8-10</a>].</p><p class="headingAnchor" id="H10530955"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical features of acromegaly are attributable to high serum concentrations of both growth hormone (GH) and insulin-like growth factor-1 (IGF-1), which is GH dependent. Excess GH and IGF-1 have both somatic and metabolic effects. The somatic effects include stimulation of growth of many tissues, such as skin, connective tissue, cartilage, bone, viscera, and many epithelial tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The metabolic effects include nitrogen retention, insulin antagonism, and lipolysis.</p><p></p><p>In addition, the somatotroph adenoma itself may cause symptoms due to its size.</p><p class="headingAnchor" id="H4"><span class="h2">Insidious onset</span><span class="headingEndMark"> — </span>The onset of acromegaly is insidious, and its progression is usually very slow. The average interval from the onset of symptoms until diagnosis is approximately 12 years [<a href="#rid11">11</a>], but determining the onset, which is usually done from old photographs, is very difficult. At diagnosis, approximately 75 percent of patients have macroadenomas (tumor diameter 10 mm or greater), and some of the adenomas extend to the parasellar or suprasellar regions [<a href="#rid12">12</a>]. Overall, approximately 60 percent of patients eventually have headaches, and 10 percent have visual symptoms [<a href="#rid1">1,13,14</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Direct effects of pituitary tumor</span></p><p class="headingAnchor" id="H6"><span class="h3">Headache/vision loss</span><span class="headingEndMark"> — </span>Some patients with acromegaly and large tumors have symptoms due to direct compressive effects of the tumor mass, such as headache, visual field defects (classically bitemporal hemianopsia), and cranial nerve palsies. In a series of 310 patients with acromegaly, headache and visual defects were reported as the presenting features in 8 and 3 percent of patients, respectively [<a href="#rid12">12</a>]. However, approximately 60 percent of patients eventually develop headaches and 10 percent develop visual symptoms [<a href="#rid1">1,13</a>]. Headache, however, may be the direct result of the elevated serum GH concentration, as well as of the mass effect. (See  <a class="medical medical_review" href="/z/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Pituitary function</span><span class="headingEndMark"> — </span>A somatotroph macroadenoma, due to its size, can cause decreased secretion of other pituitary hormones, most commonly gonadotropins [<a href="#rid13">13</a>]. Many females with acromegaly have menstrual dysfunction, with or without galactorrhea, and some have hot flashes and vaginal atrophy as a result of estrogen deficiency. In a study of 47 females of reproductive age who had acromegaly, 29 (62 percent) had amenorrhea and seven (15 percent) had oligomenorrhea [<a href="#rid15">15</a>]. Males may have erectile dysfunction, loss of libido, decreased facial hair growth, and a decrease in testicular volume.</p><p>Hyperprolactinemia occurs in approximately 30 percent of patients. In some patients, it is due to cosecretion of prolactin and GH by a somatomammotroph adenoma, in which case the serum prolactin concentration may be over 200 ng/mL. In other patients, the cause is likely interference with hypothalamic-pituitary blood flow, in which case the serum prolactin concentration will likely be less than 200 ng/mL.</p><p>In a pilot study from a multicenter acromegaly registry (363 patients), hypogonadism was present in 53 percent of patients (49 percent of males and 57 percent of females) [<a href="#rid16">16</a>]. Prevalence of hypogonadism was similar in those with macroadenomas and microadenomas (54 and 38 percent, respectively). In macroadenoma patients, hypogonadism was more common in those with coexisting hyperprolactinemia. The cause of the hypogonadism in patients with microadenomas and normal serum prolactin concentrations is unknown. (See  <a class="medical medical_review" href="/z/d/html/7460.html" rel="external">"Causes of secondary hypogonadism in males"</a>.)</p><p>Thyroid-stimulating hormone (TSH) and corticotropin (ACTH) deficiency occur less commonly than other pituitary hormonal deficiencies [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Effects of GH/IGF-1 excess</span><span class="headingEndMark"> — </span>Long-term growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess results in overgrowth of many tissues, including connective tissue, cartilage, bone, skin, and visceral organs. Other systemic complications include cardiovascular disease, sleep apnea, metabolic disorders, and colon neoplasia.</p><p class="headingAnchor" id="H9"><span class="h3">Soft tissue and skin</span><span class="headingEndMark"> — </span>Virtually all patients with acromegaly have acral and soft tissue overgrowth and skin thickening. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin </strong>–<strong> </strong>The skin thickens, making it hard to puncture, and skin tags may appear. Hyperhidrosis is common (present in around 50 percent of patients), often making the patient malodorous. Hair growth increases, and some females have hirsutism (56 percent in one series) [<a href="#rid15">15</a>]. Cutis verticis gyrata (thickening of the skin on the scalp that creates furrows and ridges) can also be seen [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jaw, hands, and feet </strong>–<strong> </strong>The characteristic soft tissue findings are an enlarged jaw (macrognathia) and enlarged, swollen hands and feet, which result in increasing shoe and glove size and the need to enlarge rings.</p><p></p><p class="bulletIndent1">The facial features become coarse, with enlargement of the nose and frontal bones as well as the jaw, and the teeth become spread apart  (<a class="graphic graphic_picture graphicRef68059 graphicRef64652" href="/z/d/graphic/68059.html" rel="external">picture 1A-B</a>). Despite the prominence of these findings at the time of diagnosis, the rate of change is so slow that few patients seek care because their appearance had changed or for other symptoms related to acral enlargement (eg, only 13 percent of 256 patients in one series [<a href="#rid12">12</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mouth</strong> – Other manifestations of soft tissue overgrowth include macroglossia and enlargement of the soft tissues of the pharynx and larynx leading to deepening of the voice and in approximately 50 percent of patients, obstructive sleep apnea. (See <a class="local">'Sleep apnea'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Carpal tunnel syndrome </strong>–<strong> </strong>Manifestations of soft tissue overgrowth also include paresthesias of the hands (eg, carpal tunnel syndrome occurs in around up to 64 percent of patients; it is often bilateral [<a href="#rid19">19</a>]). Magnetic resonance imaging (MRI) studies suggest that the pathology of median neuropathy in acromegaly is increased edema of the median nerve, which resolves rapidly with reduction of serum GH and IGF-1 concentrations [<a href="#rid20">20</a>]. However, in one report, 18 percent of patients required surgery for carpal tunnel syndrome during the course of their disease [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Carpal tunnel syndrome symptoms may improve after successful acromegaly management. In a study of eight subjects who attained acromegaly control either via surgery or adjuvant medical therapy, carpal tunnel symptoms improved in all but one [<a href="#rid22">22</a>]. Median nerve function improved, although median nerve size was unchanged. Hence, control of GH hypersecretion is accompanied by improvement in carpal tunnel syndrome findings in the majority of subjects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral neuropathy </strong>–<strong> </strong>Peripheral neuropathy occurs in approximately one-half of acromegaly patients and may contribute to muscle weakness [<a href="#rid19">19</a>]. The nerve damage may be due to fluid accumulation and soft tissue changes seen with high GH and IGF1 levels, as well as to concurrent diabetes mellitus, which develops in 30 percent of patients.</p><p></p><p class="bulletIndent1">The component due to acromegaly appears to involve segmental demyelination without evidence of axonal degeneration; there is eventual irreversible Schwann cell hypertrophy in of small diameter fibers [<a href="#rid23">23</a>]. Peripheral nerve enlargement (median, ulnar) can be detected by ultrasound and appears to be related to both degree of biochemical control as well as acromegaly duration. The enlargement of the nerves is not confined to potential entrapment areas (cubital, carpal tunnel) [<a href="#rid24">24</a>]. While nerve cross-sectional area decreases with successful treatment over a one-year follow-up period, nerves still remain larger than controls. Reduction in nerve enlargement is proportional to the degree of disease control, particularly levels of IGF-1 [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Bone and joints</span><span class="headingEndMark"> — </span>When excess GH secretion occurs in children, eg, before the epiphyses of the long bones are fused, linear growth does increase; the result is pituitary gigantism. In contrast, adults with acromegaly do <strong>not</strong> become taller. (See  <a class="medical medical_review" href="/z/d/html/5855.html" rel="external">"Pituitary gigantism"</a>.)</p><p>Synovial tissue and cartilage enlarge, causing hypertrophic arthropathy of the knees, ankles, hips, spine, and other joints [<a href="#rid21">21</a>]. Joint symptoms are a common presenting feature of the disease, and back pain (and kyphosis) is common  (<a class="graphic graphic_diagnosticimage graphicRef64058 graphicRef82074" href="/z/d/graphic/64058.html" rel="external">image 1A-B</a>). Back pain may also be due to osteoporosis caused by concurrent gonadal insufficiency due to the enlarging pituitary tumor. </p><p>While it has been suggested that acromegaly is associated with an increased risk of vertebral fractures, data are inconsistent, and adverse effects on bone may be related to the presence of hypogonadism rather than acromegaly per se [<a href="#rid26">26-35</a>]. A consensus statement has suggested that patients with acromegaly should be assessed for osteoporosis risk factors such as vitamin D deficiency, inadequate calcium intake, hyperparathyroidism, glucocorticoid over-replacement, and hypogonadism [<a href="#rid36">36</a>].In patients with vertebral fractures, we treat as we would for osteoporosis in the absence of acromegaly, although the efficacy and safety of bone active drugs have not been studied in acromegaly. Adequate control of acromegaly and treatment of hypogonadism is also important. (See  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2059.html" rel="external">"Treatment of osteoporosis in men"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Visceral enlargement</span><span class="headingEndMark"> — </span>Many visceral organs are enlarged in acromegaly, including the thyroid, heart, liver, lungs, and kidneys. Reversible prostatic enlargement is also common, even in males with hypogonadism [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H13801386"><span class="h4">Thyroid</span><span class="headingEndMark"> — </span>The thyroid enlargement may be diffuse or multinodular. In one study of 37 patients with acromegaly, 34 (92 percent) had an enlarged thyroid gland when assessed by ultrasonography; the mean thyroid size was more than five times normal [<a href="#rid38">38</a>]. In another report, 39 of 45 patients (87 percent) had palpable diffuse or multinodular goiter [<a href="#rid39">39</a>]. In one systematic review, 4 percent or patients with acromegaly also had thyroid cancer [<a href="#rid40">40</a>], higher than rates in the general population. It is unclear whether this association is due to increased GH/IGF-1 levels or enhanced ascertainment by the treating endocrinologists. Thyroid function is usually normal, but some patients with goiter have subclinical hyperthyroidism. A few patients have central hypothyroidism caused by their pituitary tumor. Thyroid function is usually normal in these patients.</p><p>Salivary gland enlargement has been described [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H3548321262"><span class="h3">Cardiovascular disease</span><span class="headingEndMark"> — </span>Cardiovascular abnormalities include hypertension, left ventricular hypertrophy, and cardiomyopathy [<a href="#rid43">43,44</a>].</p><p>The cardiomyopathy is characterized by diastolic dysfunction and arrhythmias [<a href="#rid45">45</a>]. The abnormalities are due both to hypertension (present in 43 percent of patients with active disease in one report) and to the acromegaly itself [<a href="#rid46">46</a>]. Reducing GH secretion improves some of the abnormalities of cardiac function [<a href="#rid47">47-49</a>]. A high plasma fibrinogen concentration occurs in acromegaly and is reduced when serum GH concentrations are lowered with <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid50">50</a>].</p><p>Heart failure occurs in 3 to 10 percent of patients [<a href="#rid51">51,52</a>]. Compared with patients with acromegaly without heart failure, these patients had an increase in left ventricular mass index that was largely due to chamber dilation, a reduction in left ventricular ejection fraction (42 versus 66 percent), and a significant elevation in cardiac index (4.3 versus 3.5 L/min per m<sup>2</sup>) [<a href="#rid51">51</a>].</p><p>An increased prevalence of valvular heart disease has also been reported. In a series of 40 patients with acromegaly, echocardiography demonstrated significant aortic regurgitation in 30 percent and mitral regurgitation in 5 percent; the comparable values in a control group matched for age, sex, hypertension, and left ventricular systolic function were 7 and 0 percent, respectively [<a href="#rid53">53</a>]. The risk increased with the duration of GH excess, including inadequate therapy.</p><p class="headingAnchor" id="H13"><span class="h3">Sleep apnea</span><span class="headingEndMark"> — </span>Obstructive sleep apnea may represent an additional risk factor for cardiovascular complications and excess mortality in patients with acromegaly. (See <a class="local">'Cardiovascular disease'</a> above and <a class="local">'Mortality'</a> below.)</p><p>The overall frequency of sleep apnea in patients with acromegaly is approximately 40 to 50 percent [<a href="#rid54">54-56</a>]. In most cases, craniofacial deformities, macroglossia, and enlargement of the soft tissues of the pharynx and larynx result in obstructive sleep apnea. Less commonly, patients develop central sleep apnea, which is thought to be due to altered respiratory control [<a href="#rid54">54,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">"Clinical presentation and diagnosis of obstructive sleep apnea in adults"</a>.)</p><p>Predictive factors for the development of sleep apnea include the severity of GH excess, duration of disease, obesity, older age, and male sex [<a href="#rid55">55,56</a>].</p><p>Sleep apnea symptoms gradually improve in some, but not all, patients after correction of the underlying GH excess with transsphenoidal surgery or medical therapy [<a href="#rid55">55,56,58,59</a>]. Thus, specific therapies for sleep apnea are necessary in many patients, although some require only transient therapy as the anatomic abnormalities induced by GH excess recede. (See  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly"</a> and  <a class="medical medical_review" href="/z/d/html/7695.html" rel="external">"Obstructive sleep apnea: Overview of management in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Metabolic</span><span class="headingEndMark"> — </span>In addition to high serum GH and IGF-1 concentrations, uncontrolled acromegaly is also associated with hyperinsulinism, insulin resistance, overt diabetes in approximately 30 percent of cases, and impaired glucose tolerance in a further 35 percent [<a href="#rid19">19,60-62</a>]. Some patients have hypertriglyceridemia or hypercalciuria.</p><p>Hyperphosphatemia occurs in approximately 70 percent of patients with acromegaly and is presumably due to direct stimulation of renal tubular phosphate reabsorption by IGF-1 [<a href="#rid63">63</a>]. The serum phosphate concentration usually does not exceed 5.5 mg/dL (1.8 mmol/L).</p><p class="headingAnchor" id="H15"><span class="h3">Colonic effects</span></p><p class="headingAnchor" id="H638590795"><span class="h4">Neoplasia</span><span class="headingEndMark"> — </span>Conflicting evidence suggests that acromegaly is associated with an increased risk of colonic neoplasia [<a href="#rid64">64-69</a>]. However, colon cancer mortality does appear to be increased with uncontrolled GH or IGF-1 levels. Mechanisms thought to be involved in the apparent excess risk include a trophic IGF-1 effect on the proliferation of epithelial cells [<a href="#rid70">70</a>] and reduced expression of the peroxisome proliferator-activated receptor (PPAR) gene [<a href="#rid71">71</a>] (see  <a class="medical medical_review" href="/z/d/html/2485.html" rel="external">"Molecular genetics of colorectal cancer", section on 'Modifier genes'</a>). Many of these studies are confounded by the observed bowel loop complexity and increased length and megacolon [<a href="#rid72">72,73</a>].</p><p>A number of individual studies have reported an increased risk of adenomatous colonic polyps in patients with acromegaly [<a href="#rid64">64-66,74</a>]. As an example, a prospective colonoscopy study evaluated 103 patients with acromegaly and 138 nonacromegalic controls [<a href="#rid64">64</a>]. Adenomatous polyps were found in 22 percent of patients compared with 8 percent of controls. Patients with acromegaly who are over age 50 years, male, have three or more skin tags, or have a family history of colon cancer are more likely to develop polyps [<a href="#rid74">74</a>].</p><p>An excess risk of colon cancer has also been observed, but the magnitude of risk compared with controls has been highly variable, ranging from 2- to 14-fold [<a href="#rid64">64-67,74,75</a>]. The best estimate of risk in patients with acromegaly comes from a meta-analysis of nine studies that compared colon adenoma and cancer rates in 701 acromegalic patients and 1573 control subjects [<a href="#rid68">68</a>]. Results included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In the eight studies with colon adenoma data, the frequency of adenomas was 2.5-fold higher in acromegaly patients than controls (23 versus 12 percent, pooled odds ratio [OR] 2.5, 95% CI 1.9-3.2).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the three studies with colon cancer data, the frequency of cancer was increased more than fourfold in acromegaly patients (5 versus 1 percent, pooled OR 4.4, 95% CI 1.5-12.3).</p><p></p><p>Based upon these observations, we suggest that colonoscopy be performed at baseline and then every three to four years thereafter in patients over age 50 years, especially when GH levels are not strictly controlled. This recommendation is consistent with the 2009 guidelines from the Acromegaly Consensus Group [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H638590802"><span class="h4">Diverticula</span><span class="headingEndMark"> — </span>Acromegaly also appears to be associated with an increased prevalence of colonic diverticula, as illustrated by a case-control study comparing 107 patients with cured or biochemically controlled acromegaly and 214 age- and sex-matched controls [<a href="#rid77">77</a>]. Diverticula were present on colonoscopy in 39 and 19 percent of patients with acromegaly and controls, respectively. Patients with the longest duration of active disease (&gt;11 years), after adjustment for pretreatment concentrations of GH and IGF-1 (standard deviation scores), were the most likely to develop diverticula (OR 4.2).</p><p class="headingAnchor" id="H16"><span class="h3">Other tumors</span><span class="headingEndMark"> — </span>In addition to an excess risk of colon polyps and cancer, acromegaly may be associated with other tumors [<a href="#rid78">78-80</a>]. In males, an excess number of malignant tumors including adenocarcinomas of the colon, stomach, esophagus, and melanoma were observed in a cohort of 1041 males with acromegaly  (<a class="graphic graphic_table graphicRef52927" href="/z/d/graphic/52927.html" rel="external">table 2</a>) [<a href="#rid78">78</a>]. An increased frequency of thyroid cancers [<a href="#rid81">81</a>] and uterine leiomyomata have been reported in females [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H4105042586"><span class="h3">Nonspecific symptoms</span><span class="headingEndMark"> — </span>Fatigue and weakness can be prominent symptoms. They may result from sleep apnea, cardiovascular dysfunction, neuropathy, hypogonadism, hyperglycemia, or some combination of these factors as described in this section.</p><p class="headingAnchor" id="H18"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>The mortality rate of patients with acromegaly appears to be increased. Death is primarily from cardiovascular disease, a risk that may be reduced by strict biochemical control of the disease  (<a class="graphic graphic_table graphicRef67986" href="/z/d/graphic/67986.html" rel="external">table 3</a>) [<a href="#rid1">1,2,45,82-88</a>].</p><p>The best estimate of all-cause mortality risk in patients with acromegaly and the effect of treatment comes from a meta-analysis of 16 studies published between 1970 and 2005 that compared mortality rates in acromegalic patients with those in the general population [<a href="#rid83">83</a>]. The mortality risk was reduced by therapy and may have been eliminated by cure, as illustrated by the following findings:</p><p class="bulletIndent1"><span class="glyph">●</span>The overall weighted mean standard mortality ratio (SMR) was 1.72, which represents a 72 percent increase in mortality in acromegalic patients compared with the general population. Some studies have reported an average reduction in survival of as much as 10 years [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When only studies in which over 80 percent of patients underwent transsphenoidal surgery as primary therapy were included, there was a smaller increase in weighted mean SMR (1.32). However, transsphenoidal surgery is not synonymous with cure, as the cure rate is only 80 to 90 percent when performed by the most experienced surgeons. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were four studies with postoperative biochemical data that could assess for surgical cure (serum growth hormone [GH] and insulin-like growth factor-1 [IGF-1]). When only patients considered to be cured were analyzed, there was no significant increase in mortality (weighted SMR 1.09, 95% CI 0.81-1.46).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Independent, yet significant, determinants of mortality in acromegaly include age, hypertension, GH levels, IGF-1 levels, history of prior irradiation, and coexisting corticotropin (ACTH) deficiency [<a href="#rid89">89</a>].</p><p></p><p>Although mortality is still increased in patients with acromegaly compared with control populations, rates have declined over time [<a href="#rid90">90</a>]. This is thought to be related to the more frequent use of pituitary surgery, more experienced pituitary surgeons, a decreased prevalence of hypopituitarism, and the availability of more medical treatment options. (See  <a class="medical medical_review" href="/z/d/html/6625.html" rel="external">"Treatment of acromegaly", section on 'Medical therapy'</a>.)</p><p class="headingAnchor" id="H1154499626"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116763.html" rel="external">"Society guideline links: Diagnosis and treatment of acromegaly"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16728.html" rel="external">"Patient education: Acromegaly (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2166.html" rel="external">"Patient education: Acromegaly (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H174159176"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acromegaly </strong>–<strong> </strong>Acromegaly is the clinical syndrome that results from excessive secretion of growth hormone (GH). Its annual incidence is six to eight per million people. The mean age at diagnosis is 40 to 45 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes </strong>–<strong> </strong>The most common cause of acromegaly is a somatotroph (GH-secreting) adenoma of the anterior pituitary. These adenomas account for approximately one-third of all hormone-secreting pituitary adenomas. An activating mutation of the alpha subunit of the guanine nucleotide stimulatory protein (Gs-alpha) gene is found in approximately 40 percent of somatotroph adenomas. These mutations result in constitutive activation of adenylyl cyclase, which may play a role in both cell division and excessive GH secretion by these adenomas. (See <a class="local">'Causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features - </strong>The clinical features of acromegaly are attributable to high serum concentrations of both pituitary-derived GH and liver-derived insulin-like growth factor-1 (IGF-1), which is GH dependent. Excess GH and IGF-1 have both somatic and metabolic effects. In addition, the somatotroph adenoma itself may cause local symptoms. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Onset </strong>–<strong> </strong>The onset of acromegaly is insidious, and its progression is usually very slow. The interval from the onset of symptoms until diagnosis is approximately 12 years. At diagnosis, approximately 75 percent of patients have macroadenomas (tumor diameter 10 mm or greater) and some of the adenomas extend to the parasellar or suprasellar regions. (See <a class="local">'Insidious onset'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Compressive effects </strong>–<strong> </strong>Some patients with acromegaly and large tumors have symptoms due to compressive effects of the tumor, such as headache, visual field defects (classically bitemporal hemianopsia), and cranial nerve palsies. Overall, approximately 60 percent of patients eventually have headaches, and 10 percent have visual symptoms. Macroadenomas can also cause decreased secretion of other pituitary hormones, most commonly gonadotropins. (See <a class="local">'Direct effects of pituitary tumor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acral and soft tissue overgrowth </strong>–<strong> </strong>Virtually all patients with acromegaly have acral and soft tissue overgrowth, and skin thickening. The characteristic findings are an enlarged jaw (macrognathia) and enlarged, swollen hands and feet, which result in increasing shoe and glove size and the need to enlarge rings. (See <a class="local">'Soft tissue and skin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular </strong>–<strong> </strong>Cardiovascular abnormalities include hypertension, left ventricular hypertrophy, and cardiomyopathy. (See <a class="local">'Cardiovascular disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Metabolic </strong>–<strong> </strong>In addition to high serum GH and IGF-1 concentrations, uncontrolled acromegaly is also associated with hyperinsulinism, insulin resistance, overt diabetes in 10 to 15 percent of cases, and impaired glucose tolerance in a further 50 percent. (See <a class="local">'Metabolic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Colonic effects </strong>–<strong> </strong>Patients with acromegaly appear to be at increased risk for colon polyps, colon cancer, and other tumors. (See <a class="local">'Colonic effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mortality </strong>–<strong> </strong>The mortality rate of patients with acromegaly appears to be increased, especially if strict biochemical control is not achieved. Death is primarily from cardiovascular disease. However, mortality rates have begun to decline with improvements in therapy. (See <a class="local">'Mortality'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Melmed S. Medical progress: Acromegaly. N Engl J Med 2006; 355:2558.</a></li><li><a class="nounderline abstract_t">Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 2010; 72:377.</a></li><li><a class="nounderline abstract_t">Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989; 340:692.</a></li><li><a class="nounderline abstract_t">Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987; 330:566.</a></li><li><a class="nounderline abstract_t">Hayward BE, Barlier A, Korbonits M, et al. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001; 107:R31.</a></li><li><a class="nounderline abstract_t">Zhang X, Horwitz GA, Heaney AP, et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 1999; 84:761.</a></li><li><a class="nounderline abstract_t">Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 2014; 371:2363.</a></li><li><a class="nounderline abstract_t">Melmed S, Ezrin C, Kovacs K, et al. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 1985; 312:9.</a></li><li><a class="nounderline abstract_t">Beuschlein F, Strasburger CJ, Siegerstetter V, et al. Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma. N Engl J Med 2000; 342:1871.</a></li><li><a class="nounderline abstract_t">Altstadt TJ, Azzarelli B, Bevering C, et al. Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor: case report. Neurosurgery 2002; 50:1356.</a></li><li><a class="nounderline abstract_t">Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102.</a></li><li><a class="nounderline abstract_t">Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21:597.</a></li><li><a class="nounderline abstract_t">Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. J Clin Endocrinol Metab 2000; 85:168.</a></li><li><a class="nounderline abstract_t">Ribeiro-Oliveira A Jr, Barkan A. The changing face of acromegaly--advances in diagnosis and treatment. Nat Rev Endocrinol 2012; 8:605.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Mukherjee JJ, Jenkins PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84:2731.</a></li><li><a class="nounderline abstract_t">Katznelson L, Kleinberg D, Vance ML, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf) 2001; 54:183.</a></li><li><a class="nounderline abstract_t">Brue T, Castinetti F, Lundgren F, et al. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. Eur J Endocrinol 2009; 161 Suppl 1:S11.</a></li><li><a class="nounderline abstract_t">Sánchez-Meza E, Kubelis-López DE, Ocampo-Candiani J, Chavez-Alvarez S. Prominent skin folds of the scalp provide a superficial clue in acromegaly. Lancet 2022; 400:1802.</a></li><li><a class="nounderline abstract_t">Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994; 73:233.</a></li><li><a class="nounderline abstract_t">Jenkins PJ, Sohaib SA, Akker S, et al. The pathology of median neuropathy in acromegaly. Ann Intern Med 2000; 133:197.</a></li><li><a class="nounderline abstract_t">Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005; 90:2731.</a></li><li><a class="nounderline abstract_t">Sasagawa Y, Tachibana O, Doai M, et al. Median nerve conduction studies and wrist magnetic resonance imaging in acromegalic patients with carpal tunnel syndrome. Pituitary 2015; 18:695.</a></li><li><a class="nounderline abstract_t">Dinn JJ, Dinn EI. Natural history of acromegalic peripheral neuropathy. Q J Med 1985; 57:833.</a></li><li><a class="nounderline abstract_t">Tagliafico A, Resmini E, Nizzo R, et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J Clin Endocrinol Metab 2008; 93:905.</a></li><li><a class="nounderline abstract_t">Resmini E, Tagliafico A, Nizzo R, et al. Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. Clin Endocrinol (Oxf) 2009; 71:220.</a></li><li><a class="nounderline abstract_t">Vestergaard P, Mosekilde L. Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone. Osteoporos Int 2004; 15:155.</a></li><li><a class="nounderline abstract_t">Bonadonna S, Mazziotti G, Nuzzo M, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 2005; 20:1837.</a></li><li><a class="nounderline abstract_t">Mazziotti G, Bianchi A, Bonadonna S, et al. Prevalence of vertebral fractures in men with acromegaly. J Clin Endocrinol Metab 2008; 93:4649.</a></li><li><a class="nounderline abstract_t">Mazziotti G, Bianchi A, Porcelli T, et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 2013; 98:3402.</a></li><li><a class="nounderline abstract_t">Claessen KM, Kroon HM, Pereira AM, et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 2013; 98:4808.</a></li><li><a class="nounderline abstract_t">Wassenaar MJ, Biermasz NR, Hamdy NA, et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur J Endocrinol 2011; 164:475.</a></li><li><a class="nounderline abstract_t">van Varsseveld NC, van Bunderen CC, Franken AA, et al. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults. Pituitary 2016; 19:381.</a></li><li><a class="nounderline abstract_t">Mazziotti G, Maffezzoni F, Frara S, Giustina A. Acromegalic osteopathy. Pituitary 2017; 20:63.</a></li><li><a class="nounderline abstract_t">Mazziotti G, Biagioli E, Maffezzoni F, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2015; 100:384.</a></li><li><a class="nounderline abstract_t">Battista C, Chiodini I, Muscarella S, et al. Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study. Clin Endocrinol (Oxf) 2009; 70:378.</a></li><li><a class="nounderline abstract_t">Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16:294.</a></li><li><a class="nounderline abstract_t">Colao A, Marzullo P, Ferone D, et al. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83:775.</a></li><li><a class="nounderline abstract_t">Cheung NW, Boyages SC. The thyroid gland in acromegaly: an ultrasonographic study. Clin Endocrinol (Oxf) 1997; 46:545.</a></li><li><a class="nounderline abstract_t">Kasagi K, Shimatsu A, Miyamoto S, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid 1999; 9:791.</a></li><li><a class="nounderline abstract_t">Wolinski K, Czarnywojtek A, Ruchala M. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review. PLoS One 2014; 9:e88787.</a></li><li><a class="nounderline abstract_t">Manetti L, Bogazzi F, Brogioni S, et al. Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 2002; 57:97.</a></li><li><a class="nounderline abstract_t">Thomson JA, McCrossan J, Mason DK. Salivary gland enlargement in acromegaly. Clin Endocrinol (Oxf) 1974; 3:1.</a></li><li><a class="nounderline abstract_t">Mosca S, Paolillo S, Colao A, et al. Cardiovascular involvement in patients affected by acromegaly: an appraisal. Int J Cardiol 2013; 167:1712.</a></li><li><a class="nounderline abstract_t">Pivonello R, Auriemma RS, Grasso LF, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017; 20:46.</a></li><li><a class="nounderline abstract_t">Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994; 41:95.</a></li><li><a class="nounderline abstract_t">López-Velasco R, Escobar-Morreale HF, Vega B, et al. Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 1997; 82:1047.</a></li><li><a class="nounderline abstract_t">Chanson P, Timsit J, Masquet C, et al. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113:921.</a></li><li><a class="nounderline abstract_t">Merola B, Cittadini A, Colao A, et al. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77:790.</a></li><li><a class="nounderline abstract_t">Minniti G, Moroni C, Jaffrain-Rea ML, et al. Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients. Clin Endocrinol (Oxf) 2001; 55:307.</a></li><li><a class="nounderline abstract_t">Landin-Wilhelmsen K, Tengborn L, Wilhelmsen L, Bengtsson BA. Elevated fibrinogen levels decrease following treatment of acromegaly. Clin Endocrinol (Oxf) 1997; 46:69.</a></li><li><a class="nounderline abstract_t">Damjanovic SS, Neskovic AN, Petakov MS, et al. High output heart failure in patients with newly diagnosed acromegaly. Am J Med 2002; 112:610.</a></li><li><a class="nounderline abstract_t">Bihan H, Espinosa C, Valdes-Socin H, et al. Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004; 89:5308.</a></li><li><a class="nounderline abstract_t">Pereira AM, van Thiel SW, Lindner JR, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 2004; 89:71.</a></li><li><a class="nounderline abstract_t">Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115:527.</a></li><li><a class="nounderline abstract_t">Davi' MV, Dalle Carbonare L, Giustina A, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 2008; 159:533.</a></li><li><a class="nounderline abstract_t">Rosenow F, Reuter S, Deuss U, et al. Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol (Oxf) 1996; 45:563.</a></li><li><a class="nounderline abstract_t">Roemmler J, Gutt B, Fischer R, et al. Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath 2012; 16:1247.</a></li><li><a class="nounderline abstract_t">Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007; 156:321.</a></li><li><a class="nounderline abstract_t">Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol 2004; 151:309.</a></li><li><a class="nounderline abstract_t">Wass JA, Cudworth AG, Bottazzo GF, et al. An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 1980; 12:53.</a></li><li><a class="nounderline abstract_t">Barrande G, Pittino-Lungo M, Coste J, et al. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000; 85:3779.</a></li><li><a class="nounderline abstract_t">Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004; 151:439.</a></li><li><a class="nounderline abstract_t">Quigley R, Baum M. Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 1991; 88:368.</a></li><li><a class="nounderline abstract_t">Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80:3223.</a></li><li><a class="nounderline abstract_t">Terzolo M, Reimondo G, Gasperi M, et al. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab 2005; 90:84.</a></li><li><a class="nounderline abstract_t">Bogazzi F, Cosci C, Sardella C, et al. Identification of acromegalic patients at risk of developing colonic adenomas. J Clin Endocrinol Metab 2006; 91:1351.</a></li><li><a class="nounderline abstract_t">Jenkins PJ, Besser M. Clinical perspective: acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86:2935.</a></li><li><a class="nounderline abstract_t">Rokkas T, Pistiolas D, Sechopoulos P, et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World J Gastroenterol 2008; 14:3484.</a></li><li><a class="nounderline abstract_t">Jenkins PJ, Frajese V, Jones AM, et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 2000; 85:3218.</a></li><li><a class="nounderline abstract_t">Cats A, Dullaart RP, Kleibeuker JH, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res 1996; 56:523.</a></li><li><a class="nounderline abstract_t">Bogazzi F, Ultimieri F, Raggi F, et al. Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients. J Clin Endocrinol Metab 2003; 88:3938.</a></li><li><a class="nounderline abstract_t">Resmini E, Tagliafico A, Bacigalupo L, et al. Computed tomography colonography in acromegaly. J Clin Endocrinol Metab 2009; 94:218.</a></li><li><a class="nounderline abstract_t">Renehan AG, Painter JE, Bell GD, et al. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clin Endocrinol (Oxf) 2005; 62:323.</a></li><li><a class="nounderline abstract_t">Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab 2002; 87:1909; author reply 1909.</a></li><li><a class="nounderline abstract_t">Melmed S. Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001; 86:2929.</a></li><li><a class="nounderline abstract_t">Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009; 94:1509.</a></li><li><a class="nounderline abstract_t">Wassenaar MJ, Cazemier M, Biermasz NR, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. J Clin Endocrinol Metab 2010; 95:2073.</a></li><li><a class="nounderline abstract_t">Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer 1991; 68:1673.</a></li><li><a class="nounderline abstract_t">Cohen O, Schindel B, Homburg R. Uterine leiomyomata--a feature of acromegaly. Hum Reprod 1998; 13:1945.</a></li><li><a class="nounderline abstract_t">Cheung NW, Boyages SC. Increased incidence of neoplasia in females with acromegaly. Clin Endocrinol (Oxf) 1997; 47:323.</a></li><li><a class="nounderline abstract_t">Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010; 13:242.</a></li><li><a class="nounderline abstract_t">Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83:2730.</a></li><li><a class="nounderline abstract_t">Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008; 93:61.</a></li><li><a class="nounderline abstract_t">Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89:667.</a></li><li><a class="nounderline abstract_t">Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86:293.</a></li><li><a class="nounderline abstract_t">Kauppinen-Mäkelin R, Sane T, Reunanen A, et al. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005; 90:4081.</a></li><li><a class="nounderline abstract_t">Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004; 89:1613.</a></li><li><a class="nounderline abstract_t">Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933.</a></li><li><a class="nounderline abstract_t">Sherlock M, Reulen RC, Alonso AA, et al. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94:4216.</a></li><li><a class="nounderline abstract_t">Esposito D, Ragnarsson O, Granfeldt D, et al. Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. Eur J Endocrinol 2018; 178:459.</a></li></ol></div><div id="topicVersionRevision">Topic 6633 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17167139" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Medical progress: Acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650784" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549426" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2825031" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254676" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022450" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25470569" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2981107" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acromegaly caused by secretion of growth hormone by a non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015856" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acromegaly caused by a growth hormone-releasing hormone-secreting carcinoid tumor: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769829" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systemic complications of acromegaly: epidemiology, pathogenesis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1521514" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical manifestations of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634382" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pituitary tumor registry: a novel clinical resource.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733271" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The changing face of acromegaly--advances in diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10443669" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Menstrual irregularity in women with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207632" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19684051" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36403622" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prominent skin folds of the scalp provide a superficial clue in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7934807" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Acromegaly. Clinical and biochemical features in 500 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10906834" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The pathology of median neuropathy in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741257" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25663441" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Median nerve conduction studies and wrist magnetic resonance imaging in acromegalic patients with carpal tunnel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3006115" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Natural history of acromegalic peripheral neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18073306" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19178522" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625668" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fracture risk is decreased in acromegaly--a potential beneficial effect of growth hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160741" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18827004" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prevalence of vertebral fractures in men with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23771918" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vertebral fractures in patients with acromegaly: a 3-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081732" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21257726" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048484" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27709412" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acromegalic osteopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25365312" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616713" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903574" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A consensus on the diagnosis and treatment of acromegaly complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9506725" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prostatic hyperplasia: an unknown feature of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231049" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The thyroid gland in acromegaly: an ultrasonographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482372" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24551163" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100076" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Submandibular salivary gland volume is increased in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4838005" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Salivary gland enlargement in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219077" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cardiovascular involvement in patients affected by acromegaly: an appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28224405" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050136" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Determinants of clinical outcome and survival in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100571" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2240917" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cardiovascular effects of the somatostatin analog octreotide in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370700" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11589673" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059560" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Elevated fibrinogen levels decrease following treatment of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12034409" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : High output heart failure in patients with newly diagnosed acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15531475" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term outcome of patients with acromegaly and congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715829" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Increased prevalence of regurgitant valvular heart disease in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1883121" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sleep apnea in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765561" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8977753" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sleep apnoea in treated acromegaly: relative frequency and predisposing factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241151" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322492" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of transsphenoidal surgery on sleep apnoea in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15362959" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379314" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An assessment of glucose intolerance in acromegaly and its response to medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061538" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476442" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1864951" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593429" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507515" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449330" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Identification of acromegalic patients at risk of developing colonic adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443146" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical perspective: acromegaly and cancer: a problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18567075" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10999811" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8564965" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Increased epithelial cell proliferation in the colon of patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915690" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957501" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Computed tomography colonography in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730414" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932345" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Acromegaly and colorectal cancer: risk assessment should be based on population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11443145" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Acromegaly and cancer: not a problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208732" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Guidelines for acromegaly management: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215398" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913507" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acromegaly and gastrointestinal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740454" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Uterine leiomyomata--a feature of acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373454" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Increased incidence of neoplasia in females with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20217483" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thyroid cancer is the most common cancer associated with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709939" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971431" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mortality in acromegaly: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764779" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Factors influencing mortality in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8327647" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : An audit of outcome of treatment in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15886256" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A nationwide survey of mortality in acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070920" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25356808" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Acromegaly: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808848" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29483205" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
